
Profound Medical Corp. PROF
$ 7.35
2.79%
Annual report 2023
added 12-27-2025
Profound Medical Corp. Book Value 2011-2026 | PROF
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Profound Medical Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.2 M | 52 M | 80.6 M | 97.4 M | - | - | 14.1 M | 11 M | 10.1 M | 1.37 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 97.4 M | 1.37 M | 37.2 M |
Quarterly Book Value Profound Medical Corp.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 80.6 M | - | - | - | 97.4 M | - | - | - | 14.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 97.4 M | 14.4 M | 64.1 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 69.84 | 1.14 % | $ 3.79 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Cognyte Software Ltd.
CGNT
|
217 M | $ 6.61 | 3.44 % | $ 475 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 13.85 | -0.57 % | $ 2.08 B | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
129 M | $ 31.25 | -3.85 % | $ 1.44 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-38.6 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
26.9 M | $ 3.46 | -2.26 % | $ 120 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 269.55 | 0.25 % | $ 7.61 B | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 4.63 | 3.58 % | $ 173 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 39.92 | 0.38 % | $ 5.95 K | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 74.02 | -1.5 % | $ 110 B | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
ClearPoint Neuro
CLPT
|
25.4 M | $ 15.18 | 4.3 % | $ 410 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 46.01 | -0.07 % | $ 1.43 B | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
InMode Ltd.
INMD
|
683 M | $ 13.96 | -0.14 % | $ 902 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
68.7 M | $ 10.16 | 2.11 % | $ 290 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
43.2 M | $ 23.53 | 1.64 % | $ 199 M | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
Establishment Labs Holdings
ESTA
|
53.1 M | $ 77.39 | -2.87 % | $ 2.18 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
189 M | $ 2.46 | 1.23 % | $ 144 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.54 | -0.16 % | $ 122 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 95.57 | 3.99 % | $ 12.9 B | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 2.18 | 17.84 % | $ 1.33 M | ||
|
IRadimed Corporation
IRMD
|
86.8 M | $ 100.38 | 1.3 % | $ 1.27 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 11.54 | 0.09 % | $ 889 M | ||
|
Inogen
INGN
|
174 M | $ 6.07 | 3.94 % | $ 144 M |